Education
About Us
Working with TipRanks
Follow Us
Corcept Therapeutics Inc. (CORT)
NASDAQ:CORT
CORT Stock Chart & Stats
$35.70
$0.08(0.16%)
At close: 4:00 PM EST
$35.70
$0.08(0.16%)
Day’s Range― - ―
52-Week Range$28.66 - $117.33
Previous CloseN/A
Volume78.39K
Average Volume (3M)2.09M
Market Cap
$3.80B
Enterprise Value$3.64B
Total Cash (Recent Filing)$372.15M
Total Debt (Recent Filing)$6.11M
Price to Earnings (P/E)43.6
Beta0.48
Next Earnings
May 06, 2026EPS Estimate
-0.11Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.20
Shares Outstanding106,374,020
10 Day Avg. Volume2,559,065
30 Day Avg. Volume2,090,118
Financial Highlights & Ratios
PEG Ratio-1.22
Price to Book (P/B)5.58
Price to Sales (P/S)4.75
P/FCF Ratio25.49
Enterprise Value/Market Cap0.96
Enterprise Value/Revenue4.78
Enterprise Value/Gross Profit4.86
Enterprise Value/Ebitda63.72
Forecast
1Y Price Target
$94.00Price Target Upside163.31% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering6
EPS Forecast (FY)0.37
Revenue Forecast (FY)$871.83M
Bulls Say, Bears Say
Bulls Say
Clinical Efficacy And Survival BenefitA pivotal trial showed relacorilant added to chemotherapy significantly reduced risk of death versus chemotherapy alone and showed benefits across subgroups, supporting broader clinical adoption beyond biomarker‑restricted use.
Commercial Resilience And Prescriber RelationshipsKorlym has delivered growing revenue and an expanding prescriber base while competing with generics, indicating entrenched physician and patient relationships that could help preserve market share.
Regulatory Approval PotentialNDA for relacorilant is under FDA review with a PDUFA date of July 11, 2026, and analysts assign a high probability of approval that could create a substantial new revenue stream if granted.
Bears Say
Legal And Generic Competition RiskA court ruling that reduces the ability to block generics increases the likelihood of authorized and standard generic entrants, which would accelerate erosion of Korlym sales and exclusivity.
Pricing Pressure From Lower‑priced ChannelsA rising share of prescriptions through lower‑priced authorized generic channels and expected payer demands for steeper discounts could materially reduce net price per prescription and constrain revenue growth.
Supply Chain And Fulfillment IssuesOngoing specialty pharmacy capacity constraints and a disruptive transition created a gap between prescriptions written and tablets actually sold, so achieving revenue targets depends on the new pharmacy resolving fulfillment problems.
Corcept Therapeutics News
CORT FAQ
What was Corcept Therapeutics Inc.’s price range in the past 12 months?
Corcept Therapeutics Inc. lowest stock price was $28.66 and its highest was $117.33 in the past 12 months.
What is Corcept Therapeutics Inc.’s market cap?
Corcept Therapeutics Inc.’s market cap is $3.80B.
When is Corcept Therapeutics Inc.’s upcoming earnings report date?
Corcept Therapeutics Inc.’s upcoming earnings report date is May 06, 2026 which is in 64 days.
How were Corcept Therapeutics Inc.’s earnings last quarter?
Corcept Therapeutics Inc. released its earnings results on Feb 24, 2026. The company reported $0.2 earnings per share for the quarter, missing the consensus estimate of $0.329 by -$0.129.
Is Corcept Therapeutics Inc. overvalued?
According to Wall Street analysts Corcept Therapeutics Inc.’s price is currently Undervalued.
Does Corcept Therapeutics Inc. pay dividends?
Corcept Therapeutics Inc. does not currently pay dividends.
What is Corcept Therapeutics Inc.’s EPS estimate?
Corcept Therapeutics Inc.’s EPS estimate is -0.11.
How many shares outstanding does Corcept Therapeutics Inc. have?
Corcept Therapeutics Inc. has 106,374,020 shares outstanding.
What happened to Corcept Therapeutics Inc.’s price movement after its last earnings report?
Corcept Therapeutics Inc. reported an EPS of $0.2 in its last earnings report, missing expectations of $0.329. Following the earnings report the stock price went down -0.713%.
Which hedge fund is a major shareholder of Corcept Therapeutics Inc.?
Currently, no hedge funds are holding shares in CORT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Corcept Therapeutics Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$94.00 (163.31% Upside)
$94.00 (163.31% Upside)
Blogger Sentiment
Bullish
CORT Sentiment 85%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 559.8K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.8%
Last 30 Days ▼ 5.4%
Last 30 Days ▼ 5.4%
News Sentiment
Bearish
Bullish news 25%
Bearish news 75%
Bearish news 75%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-40.35%
12-Months-Change
Fundamentals
Return on Equity
14.79%
Trailing 12-Months
Asset Growth
-0.30%
Trailing 12-Months
Company Description
Corcept Therapeutics Inc.
Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.
CORT Earnings Call
Q4 2026
0:00 / 0:00
Earnings Call Sentiment|Neutral
The call presented a mix of strong commercial momentum, robust clinical successes across multiple programs (notably ROSELLA and DAZALS), clear revenue growth and higher guidance, and resolved operational capacity with an improving commercial outlook. These positives are tempered by a significant regulatory setback for relacorilant in Cushing's syndrome, a Federal Circuit loss in the generic patent dispute, meaningful net income decline, and prior pharmacy-related supply disruptions. The pipeline and upcoming readouts provide multiple near-term catalysts, while regulatory and legal risks require attention.View all CORT earnings summariesCORT Stock 12 Month Forecast
Average Price Target
$94.00
▲(163.31% Upside)
Technical Analysis
Jazz Pharmaceuticals
―
Axsome Therapeutics
―
Rhythm Pharmaceuticals
―
Revolution Medicines
―
Legend Biotech
―
Ownership Overview
11.88% Insiders
17.29% Mutual Funds
3.32% Other Institutional Investors
45.29% Public Companies and Individual Investors